Steatohepatitis/Metabolic Liver Disease News

Significant differences in alcohol use, alcohol-related mortality and liver transplant rate by race and ethnicity underscore the need for “tailored approaches to managing” alcohol-related liver disease in the U.S., according to a researcher.

The FDA has granted breakthrough therapy designation to Boehringer Ingelheim’s survodutide for the treatment of adult patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate or advanced fibrosis.

The FDA granted breakthrough designation to Sagimet Biosciences’ denifanstat for the treatment of patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis, according to a company press release.

Nearly two-thirds of patients with excessive alcohol use and a high fibrosis-4 index were not referred for liver-related care, with fewer referrals among those with mental health disorders or alcohol-related mental health hospitalizations.

Sodium-glucose cotransporter-2 inhibitors showed similar hepatic effectiveness to glucagon-like peptide-1 receptor agonists, especially among women and younger patients, in metabolic dysfunction-associated steatotic liver disease.

Use of glucagon-like peptide-1 receptor agonists was associated with a reduced risk for progression to cirrhosis and other complications in patients with metabolic dysfunction-associated steatotic liver disease and diabetes, data showed.

Country-specific public health policies that target metabolic dysfunction-associated steatotic liver disease risk factors, such as food insecurity and physical activity, may play a key role in mitigating the global burden of disease.

An intermittent calorie restriction diet was “safe and more effective” in reducing hepatic steatosis at 12 weeks vs. a standard of care diet in metabolic dysfunction-associated steatotic liver disease, particularly among those with obesity.

Vitamin E improved serum markers of liver inflammation and histology in patients with metabolic dysfunction-associated steatotic liver disease, according to results from a systematic review and meta-analysis.

With the FDA label for Rezdiffra excluding the need for liver biopsy, experts proposed recommendations to “fill the gap” on how to leverage noninvasive tests to assess treatment response in metabolic dysfunction-associated steatohepatitis.